Hedge Funds Circle Valneva as H1 Report Looms Over a Stock in Freefall
Published on 07/23/2026 at 18:22 | Redaktion boerse-global.de
Valneva shares are clinging to a precarious position near their lowest point in a year, with the French-Austrian vaccine developer set to face its most critical test yet when it delivers first-half results on August 13. The stock has shed roughly 42 percent of its value since January, and the gap to its August 2025 record high of €5.16 has widened to nearly 59 percent.
The company will host a live webcast at 3 p.m. CET on the day of the release, offering investors their first comprehensive update since the first-quarter numbers laid bare the scale of the headwinds. Product revenue slumped 37.2 percent in the opening months of 2026, hit by a combination of one-off effects and softer demand for travel vaccines amid geopolitical tensions. Management responded by trimming the full-year revenue guidance by 7 percent, narrowing the range to between €135 million and €150 million.
The balance sheet, however, still provides some cushion. Valneva ended March with €105.3 million in cash — a figure that excludes proceeds from a successful private placement completed in April. The same month, the company launched a fresh cost-cutting program, underscoring the financial discipline required as it navigates a period of depressed commercial sales.
Short Sellers Move In
The market’s skepticism is now visible in the short book. Hedge fund D.E. Shaw disclosed a net short position of 0.69 percent in Valneva on July 17, a bet that has aged well: days later, the stock touched a fresh 52-week low of €2.08. At Thursday’s close of €2.15, the shares were trading barely 1.7 percent above that nadir.
Should investors sell immediately? Or is it worth buying Valneva?
The technical picture offers little comfort. The stock sits 8.2 percent below its 50-day moving average of €2.34 and a staggering 36.5 percent under the 200-day average of €3.38. The 14-day relative strength index has slipped to 35.5, territory that typically signals oversold conditions, though no meaningful reversal has materialized. Over the past 30 days alone, the shares have shed 8.2 percent.
The Lyme Vaccine Wild Card
For all the near-term gloom, the investment case hinges almost entirely on a single pipeline asset: the Lyme disease vaccine candidate LB6V, developed in partnership with Pfizer. First Berlin recently reaffirmed its “Buy” rating on the stock, albeit with a trimmed price target of €4.50, down from €4.80. The analyst firm’s optimism is rooted in the probability of FDA approval, which it pegs at 67 percent.
Pfizer reported positive Phase 3 topline data earlier this year, showing strong efficacy and no safety concerns. Two key milestones are expected in the second half of 2026: a pre-BLA meeting with the U.S. regulator and the formal submission of the Biologics License Application. The candidate is the only late-stage Lyme vaccine in development globally, giving Valneva a potential monopoly in a large unmet medical need.
Alongside the Lyme program, the company is advancing a Shigella vaccine candidate — the most advanced in its class worldwide — and other early-stage assets targeting global health threats. Progress across this pipeline will be a central topic during the August 13 webcast, alongside updates on cash runway and the cost-reduction measures.
Valneva at a turning point? This analysis reveals what investors need to know now.
A Binary Outcome
The constellation of factors ahead of the H1 report is unusually tense. A rising short interest is colliding with a stock that has virtually no cushion above its yearly low. Analysts remain broadly constructive, but the market is demanding tangible proof — either that the commercial business can stabilize or that the Lyme vaccine is on track for regulatory submission.
The RSI is flashing oversold, which technically leaves room for a bounce. But with D.E. Shaw positioned for further declines and the stock trading deep below both its short- and long-term moving averages, the burden of proof now falls squarely on Valneva’s management. August 13 will determine whether the narrative shifts from survival to recovery — or whether the downward spiral of the past twelve months has further to run.
Ad
Valneva Stock: New Analysis - 23 July
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
